

# Erratum to: “Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia”

Elias Jabbour,<sup>1</sup> Karamjeet S. Sandhu,<sup>2</sup> Paul Shaughnessy,<sup>3</sup> Aaron C. Logan,<sup>4</sup> Mehrdad Abedi,<sup>5</sup> Bijal D. Shah,<sup>6</sup> Michael R. Bishop,<sup>7</sup> Jae H. Park,<sup>8</sup> Daniel J. DeAngelo,<sup>9</sup> Eleni Tholouli,<sup>10</sup> Deborah Yallop,<sup>11</sup> Sridhar Chaganti,<sup>12</sup> Katharine Hodby,<sup>13</sup> Pere Barba,<sup>14</sup> Manuel Guerreiro,<sup>15</sup> Tobias Menne,<sup>16</sup> Justin Shang,<sup>17</sup> Pierre Lao-Sirieix,<sup>18</sup> Wolfram Brugger,<sup>19</sup> Karl S. Peggs<sup>20</sup> and Claire Roddie<sup>20</sup>

<sup>1</sup>University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>City of Hope National Medical Center, Duarte, CA, USA; <sup>3</sup>Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio, TX, USA; <sup>4</sup>Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California at San Francisco, San Francisco, CA, USA; <sup>5</sup>University of California Davis, Davis, CA, USA; <sup>6</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>7</sup>The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA; <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>9</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>10</sup>Manchester Royal Infirmary, Manchester, UK; <sup>11</sup>King’s College Hospital NHS Foundation Trust, London, UK; <sup>12</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; <sup>13</sup>University Hospitals Bristol NHS Foundation Trust, Bristol, UK; <sup>14</sup>Hospital Universitari Vall d’Hebron-Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>15</sup>Hospital Universitari I Politècnic La Fe, Valencia, Spain; <sup>16</sup>Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; <sup>17</sup>Autolus Therapeutics, Rockville, MD, USA; <sup>18</sup>Autolus Therapeutics, London, UK; <sup>19</sup>Autolus Therapeutics, Munich, Germany and <sup>20</sup>University College London Cancer Institute, London, UK

In the original published version of the article,<sup>1</sup> Prof. Peggs was inadvertently omitted from the list of authors. His name has been added in recognition of his contribution to the design of the tumor burden-guided dosing schedule at the University College London Cancer Institute. The corrected list of authors and their affiliations are shown above while the corrected contributions are shown below.

## References

1. Jabbour E, Karamjeet SS, Shaughnessy P, et al. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult

## Contributions

*EJ, JS, PL-S, WB, KSP, and CR designed the research and analyzed and interpreted the data. EJ, KSS, PS, ACL, MA, BDS, MRB, JHP, DJD, ET, DY, SC, KH, PB, MG, TM, KSP, and CR contributed vital new reagents or analytical tools and collected the data. JS and PL-S performed the statistical analysis. All authors performed the research and reviewed and approved the manuscript.*

patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Haematologica*. 2026;111(6):1999-2010.

**Correspondence:** E. Jabbour  
[ejabbour@mdanderson.org](mailto:ejabbour@mdanderson.org)

**Received:** May 27, 2026.  
**Accepted:** May 27, 2026.

<https://doi.org/10.3324/haematol.2026.289465>

©2026 Ferrata Storti Foundation  
Published under a CC BY license 